TV is a TF-targeting ADC, commonly used for the treatment of recurrent or metastatic cervical cancer (Heitz et al., 2023); Mirvetuximab Soravtansine (MIRV) is a FOLR1-targeting ADC, which is used for the treatment of ovarian cancer, especially in patients with high expression of folate receptor alpha (FOLR1) who are resistant to platinum-based drugs (Moore et al., 2023). Here, TF is linked to ovarian cancer.